Chicago Partners Investment Group LLC Sells 850 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Chicago Partners Investment Group LLC decreased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 14.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,225 shares of the biotechnology company’s stock after selling 850 shares during the period. Chicago Partners Investment Group LLC’s holdings in Ascendis Pharma A/S were worth $702,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in ASND. Signaturefd LLC grew its position in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Ascendis Pharma A/S in the third quarter valued at $30,000. GAMMA Investing LLC lifted its holdings in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares during the period. Thrivent Financial for Lutherans lifted its stake in Ascendis Pharma A/S by 0.3% in the third quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company’s stock valued at $11,717,000 after buying an additional 228 shares during the period. Finally, Avior Wealth Management LLC lifted its stake in Ascendis Pharma A/S by 3.0% in the third quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company’s stock valued at $1,226,000 after buying an additional 240 shares during the period.

Analysts Set New Price Targets

ASND has been the topic of several research reports. JPMorgan Chase & Co. upped their price objective on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. TD Cowen lowered their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Finally, Stifel Nicolaus upped their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $191.57.

Ascendis Pharma A/S Price Performance

NASDAQ ASND opened at $125.09 on Tuesday. The company’s 50 day simple moving average is $133.51 and its two-hundred day simple moving average is $132.77. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00. The stock has a market capitalization of $7.59 billion, a PE ratio of -15.48 and a beta of 0.64.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.